About Quiver Bioscience
Quiver Bioscience is a Healthcare company based in Cambridge (United States) founded in 2013 by Paul Roma, Graham Dempsey, and David Margulies, and was acquired by Exponential Capital in July 2023. Developer of transformational medicines for neurological disorders. Quiver Bioscience has raised $3.01 million across 17 funding rounds from investors including NIH, HHS and Exponential Capital. Quiver Bioscience offers products and services including Drug Discovery Platform, Cellular Models, and AI Analytics. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Quiver Bioscience was founded in 2013 and is based in Cambridge, United States. Medicines for neurological disorders are developed through a proprietary platform that integrates advanced human cellular models, measurement engineering, artificial intelligence, and machine learning. The lead candidate, UBE3A, targets seizure and neurodevelopment disorders. Operations focus on drug discovery in the biotechnology sector.
- Headquarters Cambridge, United States
- Founders Paul Roma, Graham Dempsey, David Margulies
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website quiverbioscience.com
- Social LinkedIn X
- Acquired by Exponential Capital (Jul 2023)
- Total Equity Funding$3.01M (USD)
in 17 rounds
- Latest Funding Round$3.01M (USD), Series B
Oct 2026
- InvestorsNIH
& 2 more
- Acquired byExponential Capital
(Jul 2023)
Products & Services of Quiver Bioscience
Quiver Bioscience offers a comprehensive portfolio of products and services, including Drug Discovery Platform, Cellular Models, and AI Analytics.
Platform for identifying therapeutic targets in neurological diseases.
Tools for producing neurons to analyze brain cell functions.
System to extract insights from cellular data for drug optimization.
Funding Insights of Quiver Bioscience
Quiver Bioscience has successfully raised a total of $3.01M across 17 strategic funding rounds. The most recent funding activity was a Series B round of $3.01 million completed in October 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.01M
- Total Rounds 17
- Last Round Series B — $3.01M
- First Round $3.76M
(Apr 2014)
- Investors Count 2
Latest 10 of 17 funding rounds of Quiver Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Quiver Bioscience
Quiver Bioscience has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and Exponential Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Exponential Capital is engaged in healthcare technology venture investments. | exponentialcap.com |
Investor details for Quiver Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Quiver Bioscience
3 people are tracked at Quiver Bioscience (3 in leadership).
| Name | Role | Group |
|---|---|---|
Paul Roma | Co-Founder | Leadership |
Graham Dempsey | Co-Founder | Leadership |
David Margulies | Co-Founder | Leadership |
Complete people profiles for Quiver Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Quiver Bioscience
4 dated milestones of Quiver Bioscience across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Quiver Bioscience is founded.
- Funding First funding round of $3.8M.
- Exit Acquired by Exponential Capital.
- Funding Latest funding round, Series B, of $3.0M.
Competitors of Quiver Bioscience
Quiver Bioscience has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Quiver Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Quiver Bioscience
The website of Quiver Bioscience (quiverbioscience.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 12.9% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Quiver Bioscience (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Quiver Bioscience
Complete news archive for Quiver Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quiver Bioscience
Quiver Bioscience was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Quiver Bioscience is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Quiver Bioscience is a funded company, having raised a total of $3.01M across 17 funding rounds to date. The company's 1st funding round was a Grant of $2.16M, raised on Apr 2014.
Quiver Bioscience was founded in 2013 and is based in Cambridge, United States. Medicines for neurological disorders are developed through a proprietary platform that integrates advanced human cellular models, measurement engineering, artificial intelligence, and machine learning. The lead candidate, UBE3A, targets seizure and neurodevelopment disorders. Operations focus on drug discovery in the biotechnology sector.
Quiver Bioscience's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Quiver Bioscience offers Drug Discovery Platform, Cellular Models, and AI Analytics.
Quiver Bioscience has 3 investors. Key investors include NIH, HHS, and Exponential Capital.
Yes. Quiver Bioscience was acquired by Exponential Capital in July 2023.